FDA advisory panel set to vote on Grail's multi-cancer blood test

A panel of independent advisers to the US Food and Drug Administration is set to vote on whether to recommend approval of Galleri, a multi-cancer blood test developed by the company Grail. The company says the test is designed to detect signals associated with up to 50 forms of cancer through a single blood sample, an approach known as multi-cancer early detection.

The vote represents a significant step in the regulatory review of a technology that has drawn considerable attention in recent years for its potential to identify cancers earlier than conventional screening methods, some of which are only recommended for a handful of specific cancer types.

Weighing potential benefits against open questions

Advisory panels made up of outside medical experts typically evaluate the available clinical evidence on a product's safety and effectiveness before offering a non-binding recommendation to the FDA, which makes the final approval decision. For a test like Galleri, key questions for the panel are likely to include how accurately it identifies true cancer signals, how it performs across different cancer types, and how results should be acted upon in clinical practice.

Multi-cancer blood tests have generated both enthusiasm and caution within the medical community. Proponents point to the potential to catch cancers at earlier, more treatable stages, while some clinicians and researchers have raised questions about false positives, false negatives, and how such tests should be integrated alongside existing, cancer-specific screening guidelines.

The panel's recommendation will not by itself change Galleri's regulatory status, but it is expected to weigh heavily on the FDA's eventual decision regarding the test.